))
Episode 22. Management of Low-Risk MDS
Manage episode 363911680 series 3369804
Contenu fourni par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA".
Here are the key studies discussed:
1. ASH choosing wisely:
https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely
2. International Consensus Classification (ICC):
https://pubmed.ncbi.nlm.nih.gov/35767897/
3. WHO classification 2022:
https://pubmed.ncbi.nlm.nih.gov/35732829/
4. IPSS-M:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008
5. Romiplostim in MDS:
https://pubmed.ncbi.nlm.nih.gov/29396092/
6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034
7. Luspatercept in MDS:
https://www.nejm.org/doi/full/10.1056/nejmoa1908892
8. Lenalidomide in MDS:
https://ascopubs.org/doi/10.1200/JCO.2015.66.0118
https://pubmed.ncbi.nlm.nih.gov/21753188/
9.Iron chelation therapy in MDS:
https://pubmed.ncbi.nlm.nih.gov/32203980/
48 episodes
Partager
